Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Loeys-Dietz Syndrome 4
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Loeys-Dietz Syndrome 4 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Loeys–Dietz syndrome type 4: disease-characteristics report

Executive summary and evidence scope

Loeys–Dietz syndrome type 4 (LDS4) is an autosomal-dominant, syndromic heritable thoracic aortic disease caused by heterozygous pathogenic variants in TGFB2, encoding transforming growth factor-β2. The defining risk is progressive aortic-root or other arterial aneurysm, dissection, or rupture, accompanied variably by craniofacial, skeletal, valvular, cutaneous, and dural manifestations. The foundational human study comprised only 15 affected individuals from eight families; consequently, most surveillance and treatment recommendations are extrapolated from pooled LDS or broader heritable thoracic aortic disease (HTAD) evidence rather than TGFB2-specific trials. (lindsay2012lossoffunctionmutationsin pages 1-3)

Evidence labels used below: LDS4-specific means human TGFB2 data; pooled LDS combines molecular subtypes; HTAD extrapolation denotes broader aortopathy evidence. This distinction is critical because recent expert synthesis suggests that TGFB2-associated dissection risk is generally lower than that associated with TGFBR1/TGFBR2 or SMAD3, although major aortic events still occur. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Table: This table summarizes compact, knowledge-base-ready facts for Loeys-Dietz syndrome type 4, distinguishing TGFB2-specific evidence from broader Loeys-Dietz syndrome guidance. It highlights causal genetics, phenotypes, surveillance and treatment practices, trials, and the most important current evidence gaps.

1. Disease information

Definition and identifiers

• Preferred name: Loeys–Dietz syndrome type 4.
• Synonyms: TGFB2-related Loeys–Dietz syndrome; TGFB2-related syndromic thoracic aortic aneurysm; TGFB2-related HTAD.
• OMIM: 614816 is commonly assigned to Loeys–Dietz syndrome 4.
• MeSH: D055947, Loeys-Dietz Syndrome, a parent-level term documented in ClinicalTrials.gov indexing. (NCT05472519 chunk 1)
• MONDO: a subtype-specific identifier could not be verified from the retrieved primary sources; use the current MONDO parent term for Loeys–Dietz syndrome and retain “type 4/TGFB2-related” as a qualifier rather than guessing an identifier.
• ICD-10-CM/ICD-11: no retrieved evidence established a dedicated LDS4 code. Coding generally uses broader congenital connective-tissue/aortic disease categories, supplemented by a molecular diagnosis.
• OMIM gene: TGFB2 is conventionally OMIM 190220; gene nomenclature should be validated against the live OMIM/HGNC release before database ingestion.

The evidence is principally aggregated disease-level literature and family cohorts, not EHR-derived population surveillance. The original report nevertheless contains individual-level clinical data for all 15 participants, aged 3–61 years. (lindsay2012lossoffunctionmutationsin pages 1-3)

Foundational primary source: Lindsay et al., Nature Genetics, published July 2012, DOI 10.1038/ng.2349. Its central abstract statement is: “Here, we report heterozygous mutations or deletions in the gene encoding the TGF-β2 ligand for a phenotype within the LDS spectrum and show upregulation of TGF-β signaling in aortic …” (truncated in the retrieved abstract). (lindsay2012lossoffunctionmutationsin pages 1-3)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The primary cause is a germline heterozygous pathogenic TGFB2 variant, most often acting through reduced functional TGF-β2 dosage. The founding series included genomic deletions, nonsense, frameshift, in-frame deletion, and missense variants: deletion alleles, p.Arg330Cys, p.Pro366His, p.Arg327Trp, p.Tyr369Cysfs26, p.Ala100_Tyr104del, and p.Tyr99. (lindsay2012lossoffunctionmutationsin pages 1-3)

Risk factors

• Genetic: possession of a pathogenic/likely pathogenic TGFB2 allele and an affected parent or family history are the established risks. Each child of a heterozygous affected person has a theoretical 50% transmission probability.
• Clinical modifiers: family history of early dissection, rapid aortic growth, widespread arterial disease, and marked systemic manifestations are used in pooled LDS risk stratification, but their quantitative effects in LDS4 have not been established. (monda2023theroleof pages 6-7)
• Hemodynamic/environmental: hypertension and activities producing marked blood-pressure surges are biologically plausible aggravators of aortic-wall stress and are managed as modifiable risks in HTAD; no LDS4-specific exposure-effect estimates exist.
• Sex, ancestry, age: no reliable LDS4-specific sex ratio, ancestry effect, or age-dependent penetrance estimate is available.

Protective factors

No protective TGFB2 allele or validated environmental protective factor has been identified. Blood-pressure control, avoidance of tobacco, and appropriately restricted rather than absent physical activity are tertiary-prevention practices, not prevention of the inherited disorder itself. Beta-blockers and angiotensin-receptor blockers (ARBs) are used to reduce hemodynamic stress, but direct LDS4 efficacy data are absent. (monda2023theroleof pages 6-7)

Gene–environment interactions

No formal TGFB2-by-smoking, diet, toxin, occupation, or exercise interaction study was found. Pregnancy, uncontrolled hypertension, and high-intensity isometric exertion plausibly interact with genetically weakened aortic tissue by increasing wall stress; these remain clinical extrapolations rather than quantified LDS4 interactions.

3. Phenotypes

The original cohort is too small for stable prevalence estimates; the counts implicit in its table should therefore not be generalized as population frequencies. All manifestations show variable expressivity, and vascular disease is typically chronic and progressive rather than episodic. (lindsay2012lossoffunctionmutationsin pages 1-3)

Cardiovascular and arterial

• Aortic-root dilatation/aneurysm—principal clinical sign; reported Z-scores were approximately 2.0–8.4. Onset can be pediatric, while complications may emerge in adulthood. Suggested HPO: Aortic root dilatation, Thoracic aortic aneurysm. (lindsay2012lossoffunctionmutationsin pages 1-3)
• Aortic dissection—a type-B dissection occurred at age 42 in the founding series. Suggested HPO: Aortic dissection. (lindsay2012lossoffunctionmutationsin pages 1-3)
• Arterial tortuosity/extra-aortic aneurysm—variable; the founding table records arterial tortuosity and a main pulmonary-artery aneurysm. Suggested HPO: Arterial tortuosity, Pulmonary artery aneurysm. (lindsay2012lossoffunctionmutationsin pages 1-3)
• Valve/congenital cardiac disease—mitral-valve prolapse or regurgitation, bicuspid aortic valve, atrial or ventricular septal defect, and supraventricular tachycardia occurred in individual patients. Suggested HPO: Mitral valve prolapse, Mitral regurgitation, Bicuspid aortic valve, Atrial septal defect, Ventricular septal defect, Supraventricular tachycardia. (lindsay2012lossoffunctionmutationsin pages 1-3)

Craniofacial and ocular

High-arched palate and retrognathia were common in the original table; downslanting palpebral fissures, hypertelorism, broad/bifid uvula, ptosis, myopia, retinal detachment, and lens opacity were variable. Ectopia lentis is not characteristic in a contemporary gene-comparison table. Suggested HPO terms include High palate, Retrognathia, Downslanted palpebral fissures, Hypertelorism, Bifid uvula, Ptosis, and Myopia. (lindsay2012lossoffunctionmutationsin pages 1-3, morisaki2024hereditaryaorticaneurysms pages 3-5)

Musculoskeletal, skin, and dura

Reported manifestations include tall stature, pectus deformity, scoliosis, arachnodactyly, clubfoot, pes planus, joint hypermobility or dislocation, striae, thin/soft skin, easy bruising, hernia, abnormal scars, livedo reticularis, dural ectasia, and Tarlov cysts. Suggested HPO terms are the correspondingly named concepts: Tall stature, Pectus excavatum/carinatum, Scoliosis, Arachnodactyly, Talipes equinovarus, Pes planus, Generalized joint hypermobility, Cutaneous striae, Thin skin, Easy bruising, Hernia, Dural ectasia, and Tarlov cyst. (lindsay2012lossoffunctionmutationsin pages 1-3)

Allergy, immunity, and quality of life

Allergy, asthma, eczema, food allergy, eosinophilic esophagitis, and inflammatory bowel disease are recognized in pooled LDS, but TGFB2-specific frequencies are unknown. A completed mechanistic study notes increased Treg/Th2 polarization, eosinophils, and total IgE in prior pooled LDS work; it did not enroll TGFB2-defined LDS4 specifically. (NCT05472519 chunk 1)

A 2024 multicenter pediatric study enrolled 42 children aged 6–18 years—36 with Marfan syndrome and only six with pooled LDS. Mean treadmill time-to-exhaustion Z-score was −3.1 (SD 2.9) for the combined group, and self-reported fatigue explained 48%–49% of fitness variance. Its abstract states: “Physical fitness is low in children with MFS or LDS and associated with self-reported fatigue.” These data support quality-of-life and rehabilitation concerns but cannot provide LDS4-specific effect estimates. Published online March 11, 2024; DOI 10.1007/s00431-024-05456-z. (warninkkavelaars2024physicalfitnessin pages 1-2)

4. Genetic and molecular information

Gene and variant interpretation

TGFB2 encodes a secreted TGF-β ligand. The disease is autosomal dominant and germline. The original data strongly support loss of function/haploinsufficiency for deletions and truncating variants, although individual missense alleles require variant-level functional and segregation assessment. (lindsay2012lossoffunctionmutationsin pages 1-3)

For knowledge-base ingestion, each variant should be normalized to the current MANE transcript and classified under ACMG/AMP criteria. A truncating/deletion allele is not automatically pathogenic without checking transcript context, nonsense-mediated decay, population frequency, segregation, and phenotype. Conversely, a VUS must not establish the diagnosis or direct predictive testing.

Pathogenic LDS4 variants are expected to be absent or exceptionally rare in population databases because the disorder is dominant and medically consequential. Exact gnomAD/TOPMed allele counts were not available in the retrieved documents and should be queried per normalized variant.

No reproducible LDS4 modifier gene, protective allele, founder mutation, anticipation mechanism, or disease-specific epigenetic signature has been established. Large deletions involving TGFB2 can cause disease, but LDS4 is not primarily an aneuploidy or recurrent translocation syndrome. (lindsay2012lossoffunctionmutationsin pages 1-3)

5. Environmental and lifestyle information

LDS4 is not caused by toxins, radiation, diet, occupation, smoking, alcohol, or infectious agents. Such exposures can affect general cardiovascular health but have not been shown to initiate LDS4. Practical management emphasizes normal cardiovascular risk reduction, avoidance of smoking/stimulants, blood-pressure control, and individualized limits on heavy isometric or collision exercise. Infectious transmission and zoonotic potential are not applicable.

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic trigger: heterozygous TGFB2 loss-of-function reduces normal TGF-β2 ligand production or availability.
2. Developmental/tissue signaling disturbance: altered ligand balance disrupts homeostatic TGF-β receptor–SMAD signaling in the aortic wall and connective tissues.
3. Paradoxical downstream signature: despite ligand loss, affected aortic tissue shows increased TGF-β signaling, the central “TGF-β paradox” of LDS. (lindsay2012lossoffunctionmutationsin pages 1-3)
4. Cellular response: vascular smooth-muscle cells and matrix-producing fibroblast/myofibroblast populations undergo abnormal mechanosensing, differentiation, and extracellular-matrix turnover.
5. Tissue injury: elastin/collagen architecture and medial integrity deteriorate, producing dilatation, tortuosity, aneurysm, and ultimately dissection or rupture.
6. Systemic manifestations: analogous developmental and matrix abnormalities affect palate/craniofacial structures, skeleton, skin, valves, and dura.

Suggested annotations are GO: TGF-beta receptor signaling pathway; SMAD protein signal transduction; extracellular matrix organization; collagen fibril organization; blood-vessel morphogenesis; response to mechanical stimulus, and CL: vascular smooth muscle cell, fibroblast, myofibroblast, vascular endothelial cell. These are mechanistically appropriate suggestions, not all directly demonstrated in LDS4.

No LDS4-specific validated metabolomic, lipidomic, proteomic, spatial-transcriptomic, single-cell, CRISPR-screen, or clinical epigenomic signature was identified. Pooled LDS work measures intracellular pSMAD2/3 in lymphocytes, but this is investigational rather than a diagnostic biomarker. (NCT05472519 chunk 1)

7. Anatomical structures affected

• Primary organs: aortic root, ascending and descending thoracic aorta, and potentially branch arteries.
• Secondary sites: aortic and mitral valves, pulmonary artery, cerebral/neck vasculature, palate and craniofacial skeleton, axial and appendicular skeleton, skin/subcutaneous connective tissue, and dura.
• Tissue: arterial tunica media, extracellular matrix, connective tissue, cardiac-valve connective tissue.
• Cells: vascular smooth-muscle cells are the principal effector population; fibroblasts/myofibroblasts and endothelial cells are plausible contributors.
• Subcellular compartments: secretory pathway/extracellular space for TGFB2 ligand; plasma-membrane receptor complex; cytosol and nucleus for SMAD signaling.

Suggested UBERON concepts include aortic root, thoracic aorta, artery, mitral valve, aortic valve, palate, skin, and dura mater. Lateralization is generally not relevant; vascular disease is segmental/systemic rather than consistently unilateral. (lindsay2012lossoffunctionmutationsin pages 1-3)

8. Temporal development

LDS4 is congenital at the molecular level and lifelong. Craniofacial or skeletal signs may be apparent in infancy or childhood, whereas arterial dilatation can be silent for years. The founding cohort included affected children as young as three and adults up to 61, demonstrating broad age-dependent ascertainment. (lindsay2012lossoffunctionmutationsin pages 1-3)

There is no validated stage system. A practical course is: molecular/systemic predisposition → detectable arterial dilatation/tortuosity → progressive aneurysm → elective repair or acute dissection/rupture → lifelong postoperative surveillance. Remission does not occur; surgery removes a high-risk segment but not the systemic arteriopathy. Critical intervention windows are diagnosis before dissection, detection of accelerated growth, pregnancy planning, and timely prophylactic surgery.

9. Inheritance and population

• Inheritance: autosomal dominant.
• Penetrance: apparently incomplete and age dependent for individual manifestations; no reliable percentage exists.
• Expressivity: markedly variable, even within families.
• Anticipation: not established.
• Mosaicism: theoretically possible for dominant disorders, but no LDS4-specific germline-mosaicism rate was found.
• Founder effects/consanguinity: none established; consanguinity is not a causal requirement.
• Carrier frequency: unknown and not meaningful as a recessive “carrier” concept; heterozygotes are at risk.

A ClinicalTrials.gov summary estimates all LDS at approximately 1/25,000–1/100,000, but this is not an LDS4 prevalence estimate. Incidence, geographic distribution, ancestry-specific burden, and male:female ratio for LDS4 remain unknown. (NCT05472519 chunk 1)

10. Diagnostics

Clinical and imaging evaluation

Diagnosis should be suspected with thoracic aortic aneurysm/dissection, arterial tortuosity, a suggestive family history, or combinations of hypertelorism/bifid uvula, pectus deformity, arachnodactyly, clubfoot, thin skin, easy bruising, or dural abnormalities. Baseline evaluation generally includes echocardiography and cross-sectional CT or MR angiography of the arterial tree. Pooled LDS guidance recommends imaging from cerebral circulation through the pelvis at diagnosis because disease may extend beyond the echocardiographic field. (monda2023theroleof pages 6-7)

There is no diagnostic blood chemistry, enzyme assay, metabolite, ECG signature, or biopsy requirement. Histopathology may show medial degeneration but is neither specific nor required.

Molecular testing

1. Use a validated multigene HTAD panel including TGFB2, TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB3, FBN1, COL3A1, ACTA2, MYH11, MYLK, PRKG1, and other curated genes when phenotype overlaps multiple disorders.
2. Ensure deletion/duplication analysis, because deletions were present in the founding LDS4 families. (lindsay2012lossoffunctionmutationsin pages 1-3)
3. Single-gene TGFB2 testing is reasonable when a familial pathogenic variant is known.
4. WES/WGS can identify sequence variants missed by a limited panel; WGS may improve structural and noncoding detection. Negative sequencing should be followed by review of copy-number coverage and periodic reanalysis.
5. CMA may detect a larger TGFB2-containing deletion but is less sensitive than sequence testing for small variants. Karyotype, FISH, mitochondrial DNA, and repeat-expansion testing are not routine LDS4 tests.
6. RNA studies may resolve splice VUS but are adjunctive, not standard first-line diagnostics.

Recent expert analysis emphasizes that early molecular diagnosis enables earlier surveillance and intervention, but pre- and post-test genetic counseling is essential because results affect relatives. Morisaki, Annals of Vascular Diseases, published March 2024; DOI 10.3400/avd.ra.24-00013. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Differential diagnosis and screening

Important alternatives are other molecular LDS types, Marfan syndrome, vascular Ehlers–Danlos syndrome, arterial tortuosity syndrome, Shprintzen–Goldberg syndrome, and nonsyndromic HTAD. Absence of ectopia lentis and the presence of arterial tortuosity or bifid uvula favor LDS over classic Marfan syndrome, but molecular confirmation is required because phenotypes overlap. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Test the familial variant in first-degree relatives (cascade testing) regardless of symptoms. Variant-positive relatives require vascular assessment; variant-negative relatives can usually avoid gene-specific serial surveillance unless family evidence suggests another cause. LDS4 is not part of routine newborn screening.

11. Outcome and prognosis

Aortic dissection or rupture is the principal avoidable cause of death. In the original LDS4 series, one type-B dissection occurred at 42 years, and valve-sparing root repairs occurred around 45, 48, and 56 mm in selected individuals; these observations show clinically important risk but do not define a safe diameter. (lindsay2012lossoffunctionmutationsin pages 1-3)

No credible LDS4-specific 5- or 10-year survival, life expectancy, mortality rate, disability-adjusted life years, or validated prognostic biomarker exists. Contemporary review tables rate TGFB2 disease as having common aortic-root aneurysm but less frequent early dissection than TGFBR1/2 or SMAD3 disease. Distal dissection can nevertheless occur despite relatively mild root enlargement, requiring lifelong whole-aorta/branch-vessel surveillance. (morisaki2024hereditaryaorticaneurysms pages 3-5)

Morbidity includes repeated imaging, medication, prophylactic or emergency surgery, pain, fatigue, exercise restrictions, and reduced school/sport/work participation. The available pediatric fitness results are pooled and too small to quantify LDS4 quality of life. (warninkkavelaars2024physicalfitnessin pages 1-2)

12. Treatment

Medical treatment

There is no cure or approved TGFB2-directed therapy. Pooled LDS/HTAD practice uses:

• Beta-blockers to reduce heart rate, contractility, and pulsatile wall stress.
• ARBs such as losartan to lower blood pressure and modulate angiotensin/TGF-β pathway cross-talk.
• Combination therapy when tolerated, individualized to age, blood pressure, ventricular function, pregnancy status, and adverse effects.

The 2023 review summarizing 2022 ACC/AHA guidance recommends beta-blocker and/or ARB treatment from diagnosis in LDS, but acknowledges that evidence is principally extrapolated rather than based on TGFB2 randomized trials. (monda2023theroleof pages 6-7)

Suggested NCIT intervention concepts: Beta-Adrenergic Receptor Blocker, Angiotensin II Receptor Antagonist, Antihypertensive Therapy. No LDS4 pharmacogenomic dosing rule is established.

Surgery and intervention

Valve-sparing aortic-root replacement is preferred when anatomy and expertise permit; composite root/valve replacement is an alternative. Pooled LDS thresholds must be individualized by gene, diameter indexed to body size, growth rate, family history, extra-aortic features, and surgical expertise. The ≥40-mm threshold quoted for high-risk TGFBR1/TGFBR2 disease should not automatically be transferred to TGFB2, whose natural history appears less aggressive; multidisciplinary gene-informed assessment is essential. (monda2023theroleof pages 6-7, morisaki2024hereditaryaorticaneurysms pages 3-5)

Routine endovascular repair in native connective-tissue aorta is approached cautiously because continued dilatation can compromise landing zones. It may be used selectively in emergencies, peripheral lesions, or where landing zones lie within prior surgical grafts. (monda2023theroleof pages 6-7)

Suggested NCIT terms: Aortic Root Replacement, Valve-Sparing Aortic Root Replacement, Bentall Procedure, Thoracic Endovascular Aortic Repair.

Supportive and advanced therapy

Physical/occupational therapy, orthopedic management, pain/fatigue care, dental/orthodontic care, allergy/gastroenterology care, and psychosocial support should be individualized. Tailored low-to-moderate dynamic exercise may improve fitness, but programs require aortic-specialist clearance. (warninkkavelaars2024physicalfitnessin pages 1-2)

No validated LDS4 gene therapy, CRISPR treatment, cell therapy, ASO/siRNA therapy, or immunotherapy is in clinical use. Activin/rapamycin findings mentioned in pooled cellular work remain preclinical and are not TGFB2 treatment evidence. (monda2023theroleof pages 6-7)

13. Prevention

Primary prevention of the inherited variant is limited to reproductive options: genetic counseling, prenatal diagnosis, and preimplantation genetic testing after a familial pathogenic variant is established. Vaccination does not prevent LDS4.

Secondary prevention consists of cascade genetic testing, presymptomatic echocardiography and head-to-pelvis vascular imaging, blood-pressure monitoring, and early detection of growth. Tertiary prevention includes antihypertensive therapy, avoidance of smoking and extreme exertional blood-pressure surges, pregnancy planning, timely prophylactic surgery, and lifelong postoperative surveillance. (monda2023theroleof pages 6-7)

Pregnancy requires preconception imaging, medication review—ARBs are contraindicated during pregnancy—and coordinated care by maternal-fetal medicine and an aortopathy team. No LDS4-specific pregnancy outcome rate was retrieved.

14. Other species and natural disease

No naturally occurring veterinary disorder confidently equivalent to human TGFB2-related LDS4 was identified. Therefore, breed-specific risk, VBO terms, veterinary prevalence, zoonosis, transmission, and cross-species contagion are not applicable. TGFB2 pathway conservation across vertebrates supports comparative biology, but engineered models should not be mislabeled as naturally occurring disease.

15. Model organisms and experimental systems

The founding work used human aortic tissue and molecular/cellular analyses to demonstrate paradoxically increased TGF-β signaling despite TGFB2 loss. This directly supports the human mechanism but does not by itself establish a fully phenocopying animal model. (lindsay2012lossoffunctionmutationsin pages 1-3)

Potential platforms include heterozygous Tgfb2 loss-of-function mice, patient fibroblasts, induced pluripotent stem-cell–derived vascular smooth-muscle or endothelial cells, and engineered three-dimensional vascular tissues. Their appropriate applications are ligand processing, SMAD signaling, lineage-specific responses, mechanosensing, matrix assembly, and drug screening. Important limitations are developmental lethality with severe Tgfb2 disruption, species-dependent aortic anatomy/hemodynamics, and failure of simple haploinsufficiency models to reproduce the full human age-dependent vascular phenotype. No retrieved study established a standardized LDS4 knock-in model, organoid, or high-throughput CRISPR screen.

Recent developments, trials, and implementation

1. Genetic testing and gene-specific risk: a 2023 HTAD review emphasized that molecular diagnosis affects surveillance, family screening, and management, while noting the absence of accurate gene-specific adverse-outcome models. Published February 2023; DOI 10.3390/diagnostics13040772. (monda2023theroleof pages 3-4)
2. Updated 2024 clinical synthesis: contemporary comparison suggests common aortic-root aneurysm but less frequent early dissection in TGFB2 than receptor-associated LDS; it nevertheless stresses distal and branch-vessel monitoring. (morisaki2024hereditaryaorticaneurysms pages 3-5)
3. I-LoDiS, NCT05472519: completed 2023, actual enrollment 60, nonrandomized blood-sampling study of pooled TGFBR1/TGFBR2 LDS and controls; outcomes included TFH-cell percentage and intracellular pSMAD2/3. It is mechanistic, not a therapeutic or LDS4 trial. ClinicalTrials.gov record. (NCT05472519 chunk 1)
4. NIH food-allergy natural history, NCT02504853: prospective protocol including LDS, food allergy, atopic dermatitis, and eosinophilic esophagitis; estimated enrollment 1,800. It investigates genetic, cellular, microbial, and biochemical pathways but is not TGFB2-specific. ClinicalTrials.gov record. (NCT02504853 chunk 1)
5. GenTAC, NCT01322165: NHLBI/NIAMS registry enrolled 3,706 people with genetically triggered thoracic aortic conditions and collected longitudinal data and biospecimens; data/samples are available through NHLBI BioLINCC. It provides real-world infrastructure but did not list TGFB2 among its original named eligibility genes. ClinicalTrials.gov record. (NCT01322165 chunk 1)

Principal evidence gaps and expert interpretation

The most consequential gap is the lack of a large, prospective TGFB2-only natural-history cohort. LDS4-specific penetrance, prevalence, growth rates, diameter-specific dissection risk, pregnancy outcomes, quality of life, drug response, surgical outcomes, and survival remain undefined. Current practice appropriately treats a pathogenic TGFB2 variant as actionable, but the most aggressive thresholds derived from TGFBR1/TGFBR2 disease should not be applied mechanically. Management should combine genotype, personal and family history, serial growth, body size, arterial distribution, and multidisciplinary aortic-team judgment. (monda2023theroleof pages 3-4, morisaki2024hereditaryaorticaneurysms pages 3-5)

Likewise, no validated protective variants, environmental triggers, modifier genes, circulating biomarkers, epigenetic classifiers, multi-omics signatures, or TGFB2-specific advanced therapies were identified. These are genuine “not available” fields for a knowledge-base record rather than evidence of absence.

References

1. (lindsay2012lossoffunctionmutationsin pages 1-3): Mark E Lindsay, Dorien Schepers, Nikhita Ajit Bolar, Jefferson J Doyle, Elena Gallo, Justyna Fert-Bober, Marlies J E Kempers, Elliot K Fishman, Yichun Chen, Loretha Myers, Djahita Bjeda, Gretchen Oswald, Abdallah F Elias, Howard P Levy, Britt-Marie Anderlid, Margaret H Yang, Ernie M H F Bongers, Janneke Timmermans, Alan C Braverman, Natalie Canham, Geert R Mortier, Han G Brunner, Peter H Byers, Jennifer Van Eyk, Lut Van Laer, Harry C Dietz, and Bart L Loeys. Loss-of-function mutations in tgfb2 cause a syndromic presentation of thoracic aortic aneurysm. Nature Genetics, 44:922-927, Jul 2012. URL: https://doi.org/10.1038/ng.2349, doi:10.1038/ng.2349. This article has 569 citations and is from a highest quality peer-reviewed journal.

2. (morisaki2024hereditaryaorticaneurysms pages 3-5): Hiroko Morisaki. Hereditary aortic aneurysms and dissections: clinical diagnosis and genetic testing. Annals of Vascular Diseases, 17:128-134, Mar 2024. URL: https://doi.org/10.3400/avd.ra.24-00013, doi:10.3400/avd.ra.24-00013. This article has 7 citations.

3. (monda2023theroleof pages 6-7): Emanuele Monda, Michele Lioncino, Federica Verrillo, Marta Rubino, Martina Caiazza, Alfredo Mauriello, Natale Guarnaccia, Adelaide Fusco, Annapaola Cirillo, Simona Covino, Ippolita Altobelli, Gaetano Diana, Giuseppe Palmiero, Francesca Dongiglio, Francesco Natale, Arturo Cesaro, Eduardo Bossone, Maria Giovanna Russo, Paolo Calabrò, and Giuseppe Limongelli. The role of genetic testing in patients with heritable thoracic aortic diseases. Diagnostics, 13:772, Feb 2023. URL: https://doi.org/10.3390/diagnostics13040772, doi:10.3390/diagnostics13040772. This article has 23 citations.

4. (monda2023theroleof pages 3-4): Emanuele Monda, Michele Lioncino, Federica Verrillo, Marta Rubino, Martina Caiazza, Alfredo Mauriello, Natale Guarnaccia, Adelaide Fusco, Annapaola Cirillo, Simona Covino, Ippolita Altobelli, Gaetano Diana, Giuseppe Palmiero, Francesca Dongiglio, Francesco Natale, Arturo Cesaro, Eduardo Bossone, Maria Giovanna Russo, Paolo Calabrò, and Giuseppe Limongelli. The role of genetic testing in patients with heritable thoracic aortic diseases. Diagnostics, 13:772, Feb 2023. URL: https://doi.org/10.3390/diagnostics13040772, doi:10.3390/diagnostics13040772. This article has 23 citations.

5. (warninkkavelaars2024physicalfitnessin pages 1-2): Jessica Warnink-Kavelaars, Lisanne E. de Koning, Annelies E. van der Hulst, Annemieke I. Buizer, Nicole Poissonnier, Laura E. Wijninga, Leonie A. Menke, Laura Muiño Mosquera, Lies Rombaut, and Raoul H. H. Engelbert. Physical fitness in children with marfan and loeys-dietz syndrome: associations between cardiovascular parameters, systemic manifestations, fatigue, and pain. European Journal of Pediatrics, 183:2421-2429, Mar 2024. URL: https://doi.org/10.1007/s00431-024-05456-z, doi:10.1007/s00431-024-05456-z. This article has 4 citations and is from a peer-reviewed journal.

6. (NCT05472519 chunk 1): Immunopathology of Loeys-Dietz Syndrome. Hospices Civils de Lyon. 2022. ClinicalTrials.gov Identifier: NCT05472519

7. (NCT01322165 chunk 1): National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions. National Heart, Lung, and Blood Institute (NHLBI). 2007. ClinicalTrials.gov Identifier: NCT01322165

8. (NCT02504853 chunk 1): Natural History and Genetics of Food Allergy and Related Conditions. National Institute of Allergy and Infectious Diseases (NIAID). 2015. ClinicalTrials.gov Identifier: NCT02504853

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.